Terms: = Colorectal cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Treatment
470 results:
1. Prognostic implications of immunohistochemistry in patients with endometrial cancer.
Anca-Stanciu MB; Manu A; Olinca MV; Coroleucă BC; Comandaşu DE; Coroleucă CA; Maier C; Brătilă E
Rom J Morphol Embryol; 2024; 65(2):185-193. PubMed ID: 39020532
[TBL] [Abstract] [Full Text] [Related]
2. Analysis of clinical characteristics of mismatch repair status in colorectal cancer: a multicenter retrospective study.
Mao J; He Y; Chu J; Hu B; Yao Y; Yan Q; Han S
Int J Colorectal Dis; 2024 Jul; 39(1):100. PubMed ID: 38967814
[TBL] [Abstract] [Full Text] [Related]
3. Erk Inhibition as a Promising Therapeutic Strategy for High IL-8-Secreting and Low SPTAN1-Expressing colorectal cancer.
Meier C; La Rocca G; Nawrot V; Fißlthaler B; Overby SJ; Hourfar K; Plotz G; Seidl C; Ziegler P; Wild P; Zeuzem S; Brieger J; Jäger E; Battmann A; Brieger A
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891846
[TBL] [Abstract] [Full Text] [Related]
4. The Relationship of Microsatellite Instability with BRAF and p53 Mutations and Histopathological Parameters in colorectal Adenocarcinoma.
Gündoğar Ö; Bektaş S; Yıldırım E; Gönüllü D
Ann Ital Chir; 2024; 95(2):181-191. PubMed ID: 38684491
[TBL] [Abstract] [Full Text] [Related]
5. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon cancer.
Wang P; Zhong W; Huang Q; Zhu Y; Chen L; Ye K
ACS Biomater Sci Eng; 2024 May; 10(5):3136-3147. PubMed ID: 38663028
[TBL] [Abstract] [Full Text] [Related]
6. [Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract] [Full Text] [Related]
7. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
D'Agostino E; Mastrodomenico L; Ponzoni O; Baldessari C; Piombino C; Pipitone S; Giuseppa Vitale M; Sabbatini R; Dominici M; Toss A
Cancer Treat Rev; 2024 May; 126():102723. PubMed ID: 38555857
[TBL] [Abstract] [Full Text] [Related]
8. Epigenetic mlh1 silencing concurs with mismatch repair deficiency in sporadic, naturally occurring colorectal cancer in rhesus macaques.
Deycmar S; Johnson BJ; Ray K; Schaaf GW; Ryan DP; Cullin C; Dozier BL; Ferguson B; Bimber BN; Olson JD; Caudell DL; Whitlow CT; Solingapuram Sai KK; Romero EC; Villinger FJ; Burgos AG; Ainsworth HC; Miller LD; Hawkins GA; Chou JW; Gomes B; Hettich M; Ceppi M; Charo J; Cline JM
J Transl Med; 2024 Mar; 22(1):292. PubMed ID: 38504345
[TBL] [Abstract] [Full Text] [Related]
9. Clonal origin and genomic diversity in Lynch syndrome-associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of mlh1 p.L582H.
Takahashi K; Yachida N; Tamura R; Adachi S; Kondo S; Abé T; Umezu H; Nyuzuki H; Okuda S; Nakaoka H; Yoshihara K
Genes Chromosomes Cancer; 2024 Mar; 63(3):e23231. PubMed ID: 38459936
[TBL] [Abstract] [Full Text] [Related]
10. A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
Liu YL; Weigelt B
Cancer; 2024 May; 130(10):1733-1746. PubMed ID: 38422006
[TBL] [Abstract] [Full Text] [Related]
11. Cold atmospheric plasma stabilizes mismatch repair for effective, uniform treatment of diverse colorectal cancer cell types.
He Y; Lu F; Jiang C; Gong F; Wu Z; Ostrikov K
Sci Rep; 2024 Feb; 14(1):3599. PubMed ID: 38351129
[TBL] [Abstract] [Full Text] [Related]
12. Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression.
Peng K; Liu Y; Liu S; Wang Z; Zhang H; He W; Jin Y; Wang L; Xia X; Xia L
Cell Oncol (Dordr); 2024 Jun; 47(3):1043-1058. PubMed ID: 38315285
[TBL] [Abstract] [Full Text] [Related]
13. Protective effect of alpha-lipoic acid and epalrestat on oxaliplatin-induced peripheral neuropathy in zebrafish.
Lee DW; Park HC; Kim DH
Muscle Nerve; 2024 Apr; 69(4):498-503. PubMed ID: 38294129
[TBL] [Abstract] [Full Text] [Related]
14. Association of a novel frameshift variant and a known deleterious variant in MMR genes with Lynch syndrome in Chinese families.
Li J; Ni H; Wang X; Cheng W; Li L; Cheng Y; Liu C; Li Y; Deng A
World J Surg Oncol; 2024 Jan; 22(1):36. PubMed ID: 38280988
[TBL] [Abstract] [Full Text] [Related]
15. [A Case of Stage Ⅳc dMMR Transverse Colon cancer with Complete Response to Combination Therapy with Immune Checkpoint Inhibitor in Stage ⅣB Lung Adenocarcinoma].
Kageyama C; Yoshimatsu K; Tanaka H; Higashida M; Ito Y; Okada T; Endo S; Fujiwara Y; Ueno T
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1114-1116. PubMed ID: 38035848
[TBL] [Abstract] [Full Text] [Related]
16. Metastasis of endometrial adenocarcinoma masquerading as a primary rectal cancer: A rare case report with literature review.
Li M; Zheng W
Medicine (Baltimore); 2023 Nov; 102(46):e36170. PubMed ID: 37986305
[TBL] [Abstract] [Full Text] [Related]
17. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in Uterine Endometrioid Carcinoma.
Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
[TBL] [Abstract] [Full Text] [Related]
18. Phase II Trial of Nivolumab in Metastatic Rare cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).
Okuma HS; Watanabe K; Tsuchihashi K; Machida R; Sadachi R; Hirakawa A; Ariyama H; Kanai M; Kamikura M; Anjo K; Hiramitsu A; Sekine S; Okita N; Mano H; Nishikawa H; Nakamura K; Yonemori K
Clin Cancer Res; 2023 Dec; 29(24):5079-5086. PubMed ID: 37819940
[TBL] [Abstract] [Full Text] [Related]
19. Glioma arising in the setting of mismatch repair deficiency-rare or are we missing it?
Goyal A; Rao S; Rishi KS; Ramaswamy V; Sadashiva N; Santosh V
Childs Nerv Syst; 2024 Jan; 40(1):233-237. PubMed ID: 37733272
[TBL] [Abstract] [Full Text] [Related]
20. Hormone Receptor-Positive Breast cancer Sensitive to Pembrolizumab: Evidence of the Pathogenicity of the mlh1 Variant 1835del3.
Kaplan HG; Whiteaker JR; Nelson B; Ivey RG; Lorentzen TD; Voytovich U; Zhao L; Corwin DJ; Resta R; Paulovich AG
J Natl Compr Canc Netw; 2023 Aug; 21(11):1110-1116. PubMed ID: 37643636
[TBL] [Abstract] [Full Text] [Related]
[Next]
